Regeneron Pharmaceuticals Inc. buy Morgan Stanley
Summary
This prediction is currently active. The BUY prediction by Morgan_Stanley currently has a performance of 14.52%. This prediction currently runs until 11.10.24. The prediction end date can be changed by Morgan_Stanley at any time. Morgan_Stanley has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 2.813% | 2.813% |
iShares Core DAX® | 4.015% | 2.971% |
iShares Nasdaq 100 | 2.755% | 0.503% |
iShares Nikkei 225® | -0.826% | -5.057% |
iShares S&P 500 | 2.330% | 0.720% |
Comments by Morgan_Stanley for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Morgan_Stanley for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
18.03.24
18.03.25
09.05.24
Regeneron Pharmaceuticals Inc.
03.11.23
03.11.24
09.05.24
Regeneron Pharmaceuticals Inc.
04.08.23
04.08.24
09.05.24